Abiopharma

🔍 Newton Charles W. (Executive)

Company: Lyell Immunopharma, Inc. (LYEL)

Report Date: 2025-08-20

Detailed Transactions and Holdings:

• Acquired 8,000 shares of Common Stock (Direct)
  Date: 2025-08-20 | Code: A | equity_swap_involved: 0 | shares_owned_after: 16,759.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,453 shares of Common Stock at $10.544 per share (Direct)
  Date: 2025-08-21 | Code: S | equity_swap_involved: 0 | shares_owned_after: 15,306.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2025-08-20 | Code: H | nature_of_ownership: Co-grantor and Co-trustee | shares_owned_after: 10,000.00 | Footnotes: F4

Footnotes:

• F1: Pursuant to performance-based restricted stock units granted to the reporting person on February 9, 2024, 4,000 shares were issued on the Transaction Date upon the achievement of certain performance criteria certified by the compensation committee of the Issuer's board of directors on the Transaction Date and 4,000 shares will be issued on August 20, 2026, subject to the reporting person providing service through such date.
• F2: Shares automatically sold to cover tax withholding obligation from settlement of vested restricted stock units.
• F3: The price reported above reflects the weighted average price of the shares sold. The sale price ranged from $10.49 to $10.64 per share. Upon request from the SEC staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price within the range set forth in this Form 4.
• F4: Shares held by The Charles & Lisa Newton Living Trust. The Reporting Person is co-trustee and co-grantor of The Charles & Lisa Newton Living Trust.